ArticleMolecular therapy. Nucleic acids2025
JAK2V617F
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-MPNs) are characterized by excessive myeloid cell proliferation due to mutations in hematopoietic stem/progenitor cells, most notably JAK2V617F mutation. This mutation leads to persistent JAK2 activation, driving genomic instability and accumulation of single-stranded DNA (ssDNA) fragments in the cytoplasm. The RNA-exosome complex, a critical ribonuclease complex, plays a key role in maintaining genomic stability by degrading damaged RNAs and processing ssDNA. In this study, we examined the effects of JAK2V617F
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.